|Array Biopharma Announces Binimetinib Continues to Advance in Clinical Development; Protalix Announces Data on Oral antiTNF|
|By Staff and Wire Reports|
|Wednesday, 23 April 2014 19:23|
Following the recent announcement by Novartis and GlaxoSmithKline that they have entered into a definitive agreement to exchange certain assets, Array BioPharma Inc. (NASDAQ: ARRY) reports that Novartis has indicated that it will continue to honor its obligations under the Array-Novartis agreement relating to binimetinib (MEK162), including obligations relating to support for ongoing clinical trials as specified in the agreement.
Array BioPharma - In April 2010, Array entered into an agreement under which Novartis received exclusive worldwide rights to binimetinib. If Novartis' binimetinib development and commercialization rights are returned to Array, Novartis is required to provide support for ongoing clinical studies as specified in that agreement.
Protalix BioTherapeutics, Inc. (NYSE: PLX) (TASE:PLX), announced today that preclinical data on oral antiTNF (PRX-106) was accepted for presentation at the Digestive Disease Week (DDW) Annual Meeting being held May 3-6 in Chicago, Illinois.
Yaron Ilan, M.D., Professor of Medicine of the Gastroenterology and Liver Units and Director of the Department of Medicine at Hebrew University-Hadassah Medical Center in Jerusalem, Israel, will present a poster titled: "A novel method for anti-TNF based-oral immunotherapy: Oral administration of a plant cell-expressed recombinant anti-TNF fusion protein for treating Crohn's disease." The poster which was accepted as late breaking research, will be presented on Tuesday, May 6 from 8:00 AM to 5:00 PM, Central Daylight Time, in the in South Hall of the McCormick Place Convention Center, Chicago. A copy of the poster will be posted on the Company's website under the Resources\Medical Presentations tab when presented in the conference.
Oral PRX-106 is the Company's proprietary plant cell recombinant antiTNF fusion protein being developed as an orally-administered treatment for immune mediated disorders. In preclinical studies, oral PRX-106 alleviated immune-mediated hepatic symptoms and reduced interferon gamma levels in a concanavalin A (ConA) inflammatory mouse model. Additionally, oral administration of PRX-106 alleviated immune mediated colitis in a well established mouse model for Inflammatory Bowel Disease, promoting serum levels of anti-inflammatory IL-10 and regulatory T-cells. The drug is also being tested for the treatment fatty liver and other immune mediated disorders.
The Company expects to initiate clinical trials as part of the oral PRX-106 development program during the next few months.
3D Systems (NYSE:DDD) announced today that its Medical Modeling™ Virtual Surgical Planning (VSP®) technology – the combination of its production grade 3D printing and personalized surgery tools – has enabled surgeons to conduct complex surgical procedures on newborn and infant patients with more confidence in safety and success.
Alliqua, Inc. (Nasdaq:ALQA), a provider of advanced wound care products, will launch its Biovance® human amniotic membrane allograft product at Booth #1208 at the Spring 2014 Symposium on Advanced Wound Care to be held at the Gaylord Palms Hotel and Convention Center in Orlando, Florida on April 23-27.
Amedisys, Inc. (Nasdaq:AMED), one of America's leading home health and hospice care companies, announced today that the company has finalized its previously announced settlement to bring to an end the civil investigation brought by the U.S. Department of Justice ("DOJ").
Baxano Surgical, Inc. (Nasdaq:BAXS), a medical device company focused on designing, developing and marketing minimally invasive products to treat degenerative conditions of the spine affecting the lumbar region, announced today the closing of its private placement of approximately $10 million aggregate principal amount of subordinated convertible debentures and warrants to purchase 9,428,000 shares of common stock to entities affiliated with two institutional investors.
Dehaier Medical Systems Ltd. (Nasdaq:DHRM), an emerging leader in development, assembly, marketing and sale of medical devices and sleep respiratory products in China, today announced that the Company attended the China International Medical Equipment Fair ("CMEF" or the "Fair"), held from April 17 to 20, 2014 in Shenzhen and cooperated with Timesco in marketing campaigns related to the Fair.
Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases, announced today that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug Application (IND) amendment to evaluate PROHEMA® in pediatric patients undergoing hematopoietic stem cell (HSC) transplantation for the treatment of hematologic malignancies.
Galectin Therapeutics (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announced today that all eight (8) patients have received their first infusion in cohort 2 of its Phase 1 clinical trial of GR-MD-02 in patients with NASH with advanced fibrosis.
Harvard Bioscience, Inc. (Nasdaq:HBIO), a global developer, manufacturer, and marketer of a broad range of solutions to advance life science, will present at the Sidoti Ninth Semiannual Micro-Cap Conference in New York City on May 9, 2014.
Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today announced a historical milestone in the Company's listing at the NASDAQ stock market, which is going on 30 years strong.
IPC The Hospitalist Company, Inc. (Nasdaq:IPCM), a leading national hospitalist physician group practice, today announced financial results for the first quarter ended March 31, 2014.
LHC Group Inc. (Nasdaq:LHCG), a national provider of post-acute care services, announced today details for the release of its results for the first quarter ended March 31, 2014.
Medical Marijuana, Inc. (OTC Pink:MJNA) is pleased to announce that its subsidiary company, HempMeds™, is participating as a sponsor and presenter during the week-long interactive educational event, "Herb Day – Online!"
Merge Healthcare Incorporated (Nasdaq:MRGE), a leading provider of innovative enterprise imaging, interoperability and clinical systems that seek to advance healthcare, announced today the scheduling of its first quarter 2014 earnings call, which will be held at 8:30 AM ET on Wednesday, April 30, 2014.
OncoMed Pharmaceuticals Inc. (Nasdaq:OMED), a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, today announced that several abstracts have been accepted for presentation at the upcoming American Society for Clinical Oncology (ASCO) Annual Meeting being held May 30 – June 3, 2014 in Chicago, IL.
Prothena Corporation plc (Nasdaq:PRTA), a clinical stage biotechnology company focused on the discovery, development and commercialization of novel antibodies for the potential treatment of diseases that involve protein misfolding or cell adhesion, announced today that an abstract was published by the XIV International Symposium on Amyloidosis (ISA) and described interim data from an ongoing Phase 1 study of NEOD001, a monoclonal antibody in clinical development for the treatment of patients with AL amyloidosis and persistent organ dysfunction, as of the abstract submission date.
Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), announced today that preclinical data on oral antiTNF (PRX-106) was accepted for presentation at the Digestive Disease Week (DDW) Annual Meeting being held May 3-6 in Chicago, Illinois.
The Spectranetics Corporation (Nasdaq:SPNC) today reported financial results for the three months ended March 31, 2014, which are in-line with preliminary results announced on April 7, 2014.
Symmetry Medical Inc. (NYSE:SMA), a leading global source of innovative medical device solutions, including surgical instruments, orthopedic implants, and sterilization cases and trays, announced today that it will release first quarter 2014 financial results for the period ending March 29, 2014 before the market opens on Thursday, May 1, 2014.
Tandem Diabetes Care®, Inc. (Nasdaq:TNDM), a medical device company and manufacturer of the t:slim® Insulin Pump, plans to release its first quarter 2014 results after the financial markets close on Tuesday, May 6, 2014.
Tauriga Sciences Inc. (OTCQB:TAUG), a diversified life sciences company with key assets that include active license agreements and a proprietary microbial powered fuel cell technology, has today confirmed that, in addition to the $900,000 it raised as previously disclosed in the Current Report on Form 8-K filed on April 4, 2014, the Company has raised additional capital exceeding $200,000 USD at the same terms.
Vical Incorporated (Nasdaq:VICL) today announced that the company will report financial results for the three months ended March 31, 2014, before the opening of trading on Thursday, May 1, and conduct a conference call and webcast to discuss the financial results and provide a company update at noon Eastern Time on Thursday, May 1.